Tuberculosis (TB) is a disease caused by the acid-fast bacillus (AFB) Mycobacterium tuberculosis. TB usually affects the lungs [pulmonary TB (PTB)], but it can also affect any other part of the body [extrapulmonary TB (EPTB)]. EPTB with no evidence of pulmonary involvement accounted for 21.1% of those with TB in 2005, which represents an increase from 16% in 1992.
Typical drug sensitive PTB can be cured by taking antimycobacterial drugs for 6 months. Drug resistant forms of EPTB and PTB are harder and more expensive to treat. The World Health Organization (WHO) advocates that all TB treatment be given under Direct Observed Therapy (DOT) to ensure cure. ' 
Characteristics of Ocular TB
The recognized association of TB with ocular disease dates to the 1700s, when iris lesions in TB patients were described. 8 Recognition of choroidal tubercles in the medical literature was first noted between 1830 and 1844. 9 The current incidence of ocular TB is uncertain. 5, 10, 11 It is estimated that 1.4% of persons with PTB develop ocular manifestations 3, 10, 12 but many patients with ocular TB have no evidence of PTB 5, [13] [14] [15] (Table 1) . Please note that the definition of tuberculosis and ocular tuberculosis varied between these studies. *Reports positive TST for all 12 cases, and CXR for 6: CRX was normal for 3 considered positive by TST.
Ocular M. tuberculosis infection is most often a result of hematogenous spread during PTB or EPTB. Infection may also occur via local spread from an active sinus or meningeal infection. Primary ocular infection in which bacilli enter the body through the conjunctiva is rare and is most likely to occur in children. 6, 27 Symptomatic disease is most commonly observed during reactivation of dormant lesions in ocular tissue rather than during the initial infection. 6, 10 Additionally, immune-mediated ocular TB can occur due to hypersensitivity to M. tuberculosis antigens from a distant focus (such as lungs). This hypersensitivity causes inflammation despite the absence of the bacterium in the eye. 4, 5, 23, 26 Phlyctenulosis, retinal vasculitis, and interstitial keratitis are examples of ocular pathology associated with M. tuberculosis infections believed to be hypersensitivity reactions. 3, 5, 16, 28 Ocular TB is often unilateral and asymmetric. 16, 22, 28 TB can cause a wide variety of ophthalmic findings, ranging from the ocular surface through the optic nerve and to the central nervous system. TB infection of the eyelid can start discretely as a minute nodule and later become lupus vulgaris (soft brownish TB nodules with ulceration and scarring), often accompanied by lymphadenopathy. 6 After choroid involvement, anterior uveitis and sclerokeratitis are among the most common manifestations of TB in the eye. 19, [29] [30] [31] Other anterior segment presentations of TB include conjunctival granulomas, phlyctenulosis, sclerokeratitis, interstitial keratitis, anterior uveitis, and iridocyclitis. 16, 30 Subsequent calcification of granulomas can impede vision, and inflammation can cause irreversible damage to ocular tissue. 6 Compared with adults, children and adolescents have higher rates of phlyctenular keratoconjunctivitis, which is found in 35% of children living in areas of high rates of TB. 3, 7 Anterior uveitis presents with mutton-fat keratic precipitates, photophobia, and floaters. 5 In patients with miliary (disseminated) TB, iris nodules are often associated with anterior uveitis. 5 Patients can also present with an intermediate uveitis pattern including ''snowball'' cellular aggregates and ''snow banks'' at the pars plana.
The most common sign of ocular TB is a choroidal mass, followed by choroiditis (Fig. 1) . 5, 10, 14, 16, 19, 22, 25, 26, [28] [29] [30] 32 This is likely caused by the extensive blood supply to the choroid which makes it susceptible to hematogenous spread of M. tuberculosis. Hematogenous dissemination is the assumed etiology of tuberculous choroidal granulomas, but more widespread inflammation in choroiditis and vasculitis is likely due to hypersensitivity. 26 Indocyanine green angiography can be useful in determining the extent of choroidal involvement. 18 Although this method is highly sensitive in detecting choroidal lesions, it is not specific to mycobacterial etiologies. 18 Massaro and other authors 29 note that choroidal tubercles can arise early in the progression of TB and may be an important early indicator of hematogenous M. tuberculosis before the development of symptomatic TB. 32 Massaro highlighted 2 autopsy studies of miliary TB in 1946, each showing that only one-fourth of the patients had been correctly diagnosed with TB before death. 29, 33 In addition to choroiditis, neuroretinitis and retinal vasculitis are common posterior segment manifestations. 10 A rare case of cystoid macular edema as the only ocular presentation of TB was reported in 2004. 20 Vitritis, geographic chorioretinitis, papillitis, subretinal abscess, tuberculoma, panophthalmitis, and endophthalmitis have also been described in TB patients. 5, 10, 19, 22 Finally, TB can involve the orbit in the form of granulomatous inflammation and fibrosis, potentially accompanied by osteomyelitis and endophthalmitis. 15 Patients with these features commonly present with proptosis and sinus discharge. 15 Eales disease is an idiopathic retinal vasculitis sometimes accompanied by vitreous hemorrhage (Fig. 2) . Eales disease has been postulated to represent a manifestation of TB because it tends to be more common in settings with a high rate of TB. However, data regarding its association with TB has been inconsistent. A prospective study of 1005 TB patients in 1986 found no cases of Eales disease. 12 On the other hand, between 1992 and 1998, Indian researchers tested epiretinal membrane samples from well-documented Eales disease patients by nested polymerase chain reaction (PCR). 34 Nearly half (47.8%) of patients with Eales disease had M. tuberculosis detected, whereas only 11% of the non-Eales controls from the same population tested positive. 34 In a later study in 2002, 20.8% of Eales disease patients and only 4.2% of the controls tested positive for M. tuberculosis by PCR of vitreous fluid. 35 Difficulty in diagnosis is compounded by the fact that both Eales disease and TB often occur in the same populations-as many as 0.74% of ophthalmic patients in India, where much of the population has LTBI, have Eales disease. Criteria for establishing a diagnosis of ocular TB are not well established and, therefore, the epidemiology of ocular TB is less certain than for TB. Lack of clear diagnostic criteria may also explain the variation of the reported incidence of ocular TB over time and geography. The regions most plagued by TB are also least equipped to screen thoroughly for ocular involvement, potentially resulting in underdetection of ocular manifestations. 6, 19, 30 In 1964, DeVoe and Locatcher-Khorazo 36 noted that the Institute of Ophthalmology at Presbyterian Hospital in New York City reported only 4 cases of ocular TB in 140,000 routine ophthalmic examinations over 30 years (0.003%).
In 1967, at a TB sanatorium in the United States, 1.46% of patients with active TB were identified as having ocular manifestations, as discussed in Thompson's 2005 review. 32 By contrast, in Spain in 1997, 100 persons with TB were chosen at random and examinations revealed 18% had ophthalmic manifestations, and 11 of the 18 were HIV+ . 37 In Malawi, Africa in 2002, 2.8% of TB patients, 94% of whom were coinfected with HIV, had choroidal granulomas suggestive of ocular TB. 38 In a recent retrospective study from India, 15 (<2%) of 766 HIV-infected patients who presented with ophthalmic complaints were found to have ocular TB, all of whom were also said to have concurrent PTB, although diagnostic criteria were not clearly described for either ocular or PTB. 22 We summarize this data in Table 2 .
The proportion of uveitis attributed to TB has been particularly variable over the last several decades. In 1944, the Wilmer Eye Institute ascribed 79% of uveitis cases to TB. 40 Ten years later, concomitant with an increased awareness of brucellosis, toxoplasmosis, and sarcoidosis, and stricter criteria for the diagnosis of ocular TB, only 22% of uveitis was attributed to TB. 40 Variable rates of uveitis attributable to TB have been reported: 0.6% of uveitis patients in Boston from 1982 to 1992; 10.5% in Saudi Arabia from 1995 to 2000; and 7.9% in Japan in 2000. 13, 41, 42 A uveitis clinic in Southern India reported 0.39% of its cases were caused be TB from 1992 to 1994. 43 According to a study in Northern India, 9.8% of uveitis cases at a referral eye clinic were caused by TB from 1996 to 2001. 44 During that same time period, 5.6% of uveitis cases at the Aravind Eye Hospital in Madurai, Tamilnadu, India were caused by TB. 45 In the United States, the decrease in the proportion of uveitis attributed to TB may reflect improved diagnostic capacity and the overall decrease in the incidence of TB. 46 Patients receiving immunosuppressive therapy are at particular risk for reactivation of LTBI in the eye and elsewhere. A 4-fold increase in TB was noted among rheumatoid arthritis patients who had received infliximab over those who had not. 47 Recent clinical trials done on patients receiving infliximab and adalimumab showed that prescreening for LTBI resulted in up to 85% fewer cases of reactivated TB. [47] [48] [49] Ophthalmologists should apply equal rigor in screening for undiagnosed LTBI when considering immunosuppression in patients with presumed autoimmune ocular disease. Both the possibility of TB masquerading as an autoimmune process or an unrelated LTBI should be explored before the initiation of immunomodulatory therapy. Ophthalmologists confronted with a patient with an autoimmune eye disease requiring immunosuppression or a possible presentation of ocular TB should assess the potential for risk factors for LTBI. According to the CDC, these factors include recent travel to and immigration from regions where TB is endemic; work in healthcare; infection with HIV; work and residence in high-risk congregate housing; low income and access to medical care; intravenous drug use; and Please note that the definition of tuberculosis and ocular tuberculosis varied between these studies. *We were interested in the average without data from the Donahue study because of the large number of patients in that study.
previous tests consistent with LTBI. 50 Screening strategies for diagnosis of LTBI are discussed later in this text.
HIV and TB promote each other's virulence. Persons living with HIV are more likely to progress from LTBI to TB, to have atypical presentations including EPTB, and to be more difficult to diagnose. For these reasons, TB is a leading cause of death of HIV patients worldwide. Active TB has been associated with an increase in viral load and decrease in CD4 lymphocytes. 6 Africa's TB incidence has tripled in concert with rising levels of HIV, and HIV is considered the primary reason for the increase in TB in the United States in the 1990s. 30, 51 Five percent of immunocompetent persons infected with TB advance immediately to active disease, compared with 40% of HIV-positive patients. 2, 5 Similarly, EPTB, which is associated with disseminated disease, affects 21% of immunocompetent TB patients and over 50% of those who are HIV-positive. 1, 52, 53 The implications for ocular TB in the presence of HIV infection are less clear. A large study in Chennai, India from 1993 to 2005 found the incidence of ocular TB in HIV patients to be 1.95%. 22 A study from the same population reported that 1.39% of patients with active PTB and EPTB had ocular TB, suggesting that the HIV coinfection does not dramatically increase the rate of ocular TB. 12 The relatively high prevalence of EPTB and disseminated TB in HIV patients does not seem to be reflected in increased cases of ocular TB. 2, 22 Like non-HIV patients, among HIV-infected patients with ocular TB in these studies, choroidal granulomas were the most common presentation. However, there was a relatively high rate of panophthalmitis due to TB compared with data from immunocompetent individuals. 22 ' Challenges Toward the Diagnosis of Ocular TB The diagnosis of ocular TB is important because prompt treatment may improve the individual patient's outcome. Delayed diagnosis can lead to pain, vision loss, and systemic complications of the infection. Diagnosis is also important from a public health perspective because identification and treatment of coexisting PTB may prevent TB transmission to others. Unfortunately, there is no pathognomonic ophthalmic finding for ocular TB. Ocular TB is difficult to diagnosis due to its similarity to other causes of uveitis, the invasiveness of obtaining tissue samples, and limitations of available diagnostic tests. Clinician suspicion is an imperative first step toward the correct diagnosis. [3] [4] [5] [6] 17, 19, 23, 26, 30, 36 ' Diagnostic Tests for TB The diagnosis of ocular TB is most certain if M. tuberculosis is cultured from the eye. This is rarely possible, either because of difficulties in acquiring a specimen or unavailability of mycobacterial culture facilities. Histologic examination of an ocular biopsy specimen can be suggestive of the diagnosis. Although not necessary for the diagnosis, caseating granulomas are a sensitive finding of the histology of M. tuberculosis infection. 4, 6, 10 In a patient with consistent ocular features, but without microbiologic confirmation from the eye, the diagnosis of TB from another anatomic site can be helpful. The first step in the investigation for evidence of TB is a thorough history and physical examination. The characteristics and availability of TB diagnostic technology (varies substantially worldwide) are described in several recent reviews. 54, 55 The WHO recommends sputum microscopic examination to establish the diagnosis of PTB because the method detects the most infectious TB cases, it is highly specific, inexpensive, and widely established. 56 However, it is difficult to maintain capacity and expertise for reliable sputum microscopy, it requires repeat patient visits and is insensitive (35% to 70%; requiring 5000 to 10,000 bacteria/mL of sputum) especially in HIV patients, children, and EP disease. 57 AFB smear is also unable to distinguish among mycobacterial species, and between drug-resistant and drug-sensitive M. tuberculosis.
In settings with mycobacterial culture capacity, sputum, blood, cerebrospinal fluid, lymph node, or any other site implicated as infected by physical examination should be cultured if AFB sputum smear is negative. Sputum culture detects 80% of TB cases with >98% specificity, is more sensitive than smear (requires 10 to 100 bacteria/mL of sputum), allows species identification, and allows drug susceptibility testing. [58] [59] [60] Limitations include that culturing is slow (2 to 6 wk); and that it requires specialized personnel, equipment, water, and electricity.
Radiography can suggest active or remote PTB, which in turn can support a diagnosis of ocular TB. Advantages of radiography include convenience, routine availability in developed country settings, and high sensitivity in HIV-negative patients. The results may also be relevant in diagnosing sarcoidosis that is often a possibility when a diagnosis of ocular TB is being considered. Limitations of radiology as a method to diagnosis TB are that it is nonspecific and especially unreliable for HIVinfected person. In resource-limited settings, it is considered expensive, and has limited availability at point-of-care clinics because it requires specialized equipment and a power source. 55, 61 Nucleic acid amplification (NAA) methods may represent a significant improvement for TB diagnosis. Parts of the M. tuberculosis genome are amplified and bound to a signal-generating probe to allow detection. Tests based on NAA are rapid and usually highly specific for M. tuberculosis (close to 100%), with excellent sensitivity (>95% in smear-positive, 60% to 70% in smear-negative sputum specimens). [62] [63] [64] Limitations of NAA tests include cost and complexity. Currently, NAA tests are used primarily for confirmation of smear positive results or for primary case finding in combination with other methods. Because of their price and complexity, the use of these methods is still limited to developed countries. 55 Ocular samples have also been analyzed using NAA tests in a number of studies. 11, 34, [65] [66] [67] [68] [69] The probes used often differ between clinical sites as does the criteria for interpretation, depending on the population tested. For instance, in the study of Eales disease discussed earlier, although 47.8% of patients with Eales disease had M. tuberculosis detected by PCR in their epiretinal membranes, 11% of the non-Eales control patients from the same population tested positive. 34 Although supportive of the association between Eales and TB, this study also reveals the high background rate of TB detectable by PCR in ocular specimens from a population of patients presumed not to have TB-related ocular disease. The rate of PCR-positive tests for M. tuberculosis among patients with Eales and controls was lower, 20.8% and 4.2%, respectively, in a 2002 study which examined vitreous samples rather than epiretinal membranes. 35 These different rates of positive PCR tests among Eales patients and controls suggest that the ability to detect DNA from M. tuberculosis in Eales and perhaps other forms of ocular TB may depend of the ocular tissue sampled.
Reliable, serologic tests for TB diagnosis have been a goal for TB control for many years. There are many theoretic advantages, but field testing of this technology has repeatedly shown poor sensitivity and inability to distinguish between TB, Bacillus Calmette-Guérin (BCG), LTBI, and nontuberculous mycobacteria. 55 Mycobacteriophage assay is a method that uses viruses that infect mycobacteria to demonstrate the presence of M. tuberculosis. 70 This technology is not yet widely available.
Other novel technologies for TB diagnosis include those that are based on detection of mycobacterial antigens. For example, during TB disease, M. tuberculosis cells are lysed by the host immune system, metabolized, and DNA and carbohydrate antigens such as lipoarabinomannan are released into the blood, filtered by the kidneys, and can be detected in the urine. Preliminary studies to detect lipoarabinomannan and the transrenal DNA in the urine are so far promising, PCR has been used and shown good sensitivity in preliminary studies. [71] [72] [73] [74] [75] Larger studies under field conditions among TB suspects are needed. Advantages of these approaches include ease of specimen collection, less generation of infectious aerosols during collection compared with sputum, and because tests are based on the detection of antigen, performance is not limited by the status of the immune system of the patient. ' 
Diagnosis of LTBI
In highly TB endemic settings where most of the population has evidence of LTBI, the diagnosis of ocular TB is not meaningfully influenced by confirmation of LTBI. However, in settings where TB is less common (such as the United States and Western Europe), the diagnosis of ocular TB may be considered more likely by diagnosis of LTBI. There are 2 tests that can be used to detect LTBI. The Mantoux tuberculin skin test (TST) is performed by injecting a small amount of fluid containing antigens of M. tuberculosis (called tuberculin) into the skin in the lower part of the arm. A person given the TST must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
A second type of test to detect LTBI is the interferon gamma release assays (IGRAs). These are blood tests that measure how the patient's immune system reacts to M. tuberculosis. The QuantiFERON-TB Gold test (QFT-G) is an IGRA, which is approved in the United States for immunocompetent persons. The T Spot TB Test is an IGRA that is widely used elsewhere in the world and is under consideration for licensure in the United States. A positive TSTor IGRA only indicates that a person has LTBI. It does not tell whether or not the person has TB disease. Other tests, such as a chest x-ray and a sample of sputum, are needed to see whether the person has PTB disease.
BCG is a TB vaccine that contains a strain of the closely related bacteria, Mycobacterium bovis. BCG is used in many countries, but it is not generally recommended in the United States. BCG vaccination does not completely prevent people from getting TB. It may also cause a falsepositive TST. To detect LTBI in persons who have been vaccinated with BCG, the IGRAs are preferred to the TST because of less cross-reaction to the BCG.
The T SPOT-TB (Oxford Immunotec, Oxford, UK) has been shown to give very high sensitivity (97%) in active TB 76 and has been used in a number of contact tracing situations where it has shown high correlation to the amount of exposure. 77, 78 The QuantiFERON-Gold (Cellestis Limited, Victoria, Australia) has demonstrated a specificity of 98.1% among 216 BCG-vaccinated Japanese nursing students who were entering their training and considered at low risk for LTBI. A sensitivity of 89.0% was reported in 118 patients with culture-confirmed TB. 79 In another study, QFT-G was compared with TST by using 2 tuberculin units of RT-23. In a group of 99 healthy, BCG-vaccinated medical students in Korea, the specificity of QFT-G was 96%, compared with 49% for the TST. Among 54 patients with PTB disease, the sensitivity of the QFT-G was 81%, compared with 78% for the TST. 80 QFT-G and the TST were compared in an unselected population of 318 hospitalized patients. 81 QFT-G had greater sensitivity for TB disease (67%) than did TST (33%), but indeterminate QFT-G responses were common (21%) among patients with negative TST results, the majority of whom were thought to be immunocompromised or immunosuppressed. 82 The sensitivity of these tests is reduced during active TB and during any immunocompromised state, whether by medication, overwhelming TB infections (such as miliary TB), comorbid illness, or HIV. The utility of these tests in ocular TB is uncertain and stems from our lack of understanding as to whether ocular TB represents active TB similar to other well-described forms of EPT. Studies from 1996 to 2006, which we reviewed, indicate that approximately 52% of these cases of ocular TB were associated with active TB elsewhere ( Table 1) . If ocular TB is a form of active TB, a positive TST or IGRA may be helpful if positive in establishing TB exposure, but there may also be reduced sensitivity of these tests as there is in other forms of active TB. Alternatively, if ocular TB is not associated with a generalized reduction in the maintenance of immune-mediated TB latency, responses to TST and IRGA may be normal and possibly enhanced during active ocular TB. If this is the case, a negative or minimally reactive TST or IRGA may be very helpful in ruling out ocular TB whereas an enhanced response may be helpful in establishing the proper diagnosis. In practice, many clinicians working in populations with a high prevalence of TB use a robust response to TST to support the diagnosis of ocular TB in patients with characteristic clinical findings. However, in a report of 1005 patients with active TB, there was no statistically significant association of a positive Mantoux test and ocular TB. 12 The results may have been different in patients without evidence of active PTB or EPTB, but more study is warranted to explore these competing hypotheses and to understand the value of these tests in patients with presumed ocular TB (Tables 1, 2) . ' 
Suggested Diagnostic Approach for Ocular TB
Testing for TB by ophthalmologists usually occurs in response to 2 clinical situations: (1) screening of patients for LTBI who are candidates for immunosuppressive therapy, but are not suspected of having ocular TB and (2) screening of patients suspected of having ocular TB.
(1) Testing to exclude LTBI begins with an appropriate history for risk factors for TB. In a patient from a population with a low incidence of TB and no additional personal risk factors for TB, a TST or IGRA should be ordered. If this is negative no further work up is necessary. Many uveitis specialists routinely order chest x-rays when evaluating patients because of their value in both TB and sarcoidosis. If the TST or IGRA suggest LTBI, a chest x-ray should be obtained and if the chest x-ray reveals findings consistent with TB, a sputum sample should be obtained for smear and culture. At this point in the evaluation, consultation with an infectious disease specialist is usually warranted.
If the sputum is positive, antituberculosis therapy (ATT) should be initiated and the patient reported to the health department. If the sputum is negative, consideration should be given to a trial of ATT for culture-negative TB. In this scenario, the new IGRAs may be helpful in streamlining the evaluation of patients as they are simpler than skin testing in that they do not require patient follow up. A small study, 12 patients, compared TST to IGRA, QuantiFERON-TB test, for screening ophthalmology patients before immunosuppressive therapy and found similar results between the 2 methodologies. 23 It should be noted that this study used a first generation IGRA. More recently developed IGRA tests, as discussed previously, seem to be more specific than TST in patients previously vaccinated with BCG. 23 In a patient from a population with a high incidence of TB, exposure can be assumed and the history should be focused more on eliciting symptoms of active TB. In a patient without symptoms of TB, a TST or IGRA may be helpful in this diagnosing LTBI, but as stated earlier both are unreliable in active TB. Many physicians proceed directly to a chest x-ray when screening patients with significant risk factors for LTBI before immunosuppression. If chest x-ray is negative, immunosuppression is given. If it is positive or there are other signs or symptoms of TB, the patient is referred to an infectious disease specialist for evaluation before initiating immunosuppression.
(2) The diagnosis of ocular TB depends on several lines of evidence. First, the patient must have a characteristic lesion. Although ocular TB should be at least fleetingly considered in all cases of uveitis and retinal vasculitis, choroidal granulomas should raise particular concern for the possibility of ocular TB, as should granulomatous uveitis unresponsive to steroid treatment. Second, exposure to TB has to be established. In patients from populations in which there is a high incidence of TB, this can be taken for granted. In patients from populations with a low incidence of TB, evidence of LTBI can be established as described above. However, it must be kept in mind that TST and IGRA may be unreliable in patients with active TB. Thus, negative testing for LTBI does not exclude the possibility of ocular TB. Third, evidence of active TB should be pursued. In some cases, patients will have obvious findings such as active pulmonary disease or lymph nodes. However, in other cases, the findings will be more subtle. In these cases a chest x-ray is warranted. If this shows evidence of TB, the sputum should be evaluated. If the sputum shows evidence of TB, then ATT should be started and the health department notified. In patients with a positive chest x-ray but negative sputum, consideration should be given to an empiric trial of ATT to see if there is improvement in the ocular findings during the course of this treatment. This empiric trial, also known as the Schlaegel test, was traditionally a course of INH for 3 weeks while monitoring for a clinical response to treatment. 83 In the era of drug resistant TB, many ophthalmologists advocate a similar trial, but employ 3 or 4 drugs with activity against M. tuberculosis. A therapeutic response to ATT is taken as evidence of ocular TB and treatment is continued. In sum, the diagnosis of ocular TB remains a challenge. Prospective studies with strict criteria for the diagnosis of TB and ocular TB are necessary to better define the incidence of ocular TB. Although new testing methodologies for TB are promising, the utility of these has yet to be established in patients with ocular TB and thus research on their application to ocular TB is also warranted. Finally in cases in which uncertainty about TB remains, biopsy of the eye for culture, histologic examination, and/or NAA testing may be useful to establish the diagnosis of ocular TB.
